Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

Background: Programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitions are being strongly recommended for the treatment of various cancers, while the efficacy of PD-1/PD-L1 inhibitions varies from individuals. It is urgent to explore some biomarkers to screen the most appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jiaxin, Zhang, Tiantian, Li, Jiahao, Lin, Junming, Liang, Wenhua, Huang, Wenjie, Wan, Ning, Jiang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587434/
https://www.ncbi.nlm.nih.gov/pubmed/31258479
http://dx.doi.org/10.3389/fphar.2019.00673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587434/
https://www.ncbi.nlm.nih.gov/pubmed/31258479
http://dx.doi.org/10.3389/fphar.2019.00673

Ejemplares similares